Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Role of Hydroxychloroquine in Covid-19 Treatment: A Systematic Review and Meta-Analysis Publisher Pubmed



Shamshirian A1, 2 ; Hessami A3, 4 ; Heydari K2, 3 ; Alizadehnavaei R2 ; Ebrahimzadeh MA5 ; Yip GW6 ; Ghasemian R7 ; Sedaghat M8 ; Baradaran H9 ; Yazdi SM10 ; Aboufazeli E11 ; Jafarpour H3 ; Dadgostar E12 ; Tirandazi B13 Show All Authors
Authors
  1. Shamshirian A1, 2
  2. Hessami A3, 4
  3. Heydari K2, 3
  4. Alizadehnavaei R2
  5. Ebrahimzadeh MA5
  6. Yip GW6
  7. Ghasemian R7
  8. Sedaghat M8
  9. Baradaran H9
  10. Yazdi SM10
  11. Aboufazeli E11
  12. Jafarpour H3
  13. Dadgostar E12
  14. Tirandazi B13
  15. Sadeghnezhad R14
  16. Karimifar K15
  17. Eftekhari A15
  18. Shamshirian D16

Source: Annals of the Academy of Medicine Singapore Published:2020


Abstract

Objective: A systematic review and meta-analysis was carried out to examine the role of hydroxychloroquine (HCQ) in the treatment of COVID-19. Methods: We performed a systematic search in PubMed, Scopus, Embase, Cochrane-Library, Web of Science, Google Scholar, and medRxiv pre-print databases using available MeSH terms for COVID-19 and hydroxychloroquine. Data from all studies that focused on the effectiveness of HCQ with or without the addition of azithromycin (AZM) in confirmed COVID-19 patients, which were published up to 12 September 2020, were collated for analysis using CMA v.2.2.064. Results: Our systematic review retrieved 41 studies. Among these, 37 studies including 45,913 participants fulfilled the criteria for subsequent meta-analysis. The data showed no significant difference in treatment efficacy between the HCQ and control groups (RR: 1.02, 95% CI, 0.81–1.27). Combination of HCQ with AZM also did not lead to improved treatment outcomes (RR: 1.26, 95% CI, 0.91–1.74). Furthermore, the mortality difference was not significant, neither in HCQ treatment group (RR: 0.86, 95% CI, 0.71–1.03) nor in HCQ plus AZM treatment group (RR: 1.28, 95% CI, 0.76–2.14) in comparison to controls. Meta-regression analysis showed that age was the factor that significantly affected mortality (P<0.00001). Conclusion: The meta-analysis found that there was no clinical benefit of using either HCQ by itself or in combination with AZM for the treatment of COVID-19 patients. Hence, it may be prudent for clinicians and researchers to focus on other therapeutic options that may show greater promise in this disease. © 2020, Academy of Medicine Singapore. All rights reserved.
Other Related Docs
6. Remdesivir: A Quick Review of Pharmacotherapy, New Emirates Medical Journal (2024)
18. A Comprehensive Review of Therapeutic Options for Covid-19, Ethiopian Journal of Health Development (2022)
19. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)